{"name":"Aciex Therapeutics, Inc.","slug":"aciex-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"neuroscience","drugs":[{"name":"AC-170 0%","genericName":"AC-170 0%","slug":"ac-170-0","indication":"Type 2 diabetes","status":"phase_3"},{"name":"AC-170 0.05%","genericName":"AC-170 0.05%","slug":"ac-170-0-05","indication":"Type 2 diabetes","status":"phase_2"},{"name":"AC-170 0.1%","genericName":"AC-170 0.1%","slug":"ac-170-0-1","indication":"Type 2 diabetes","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"AC-150 Combo","genericName":"AC-150 Combo","slug":"ac-150-combo","indication":"Other","status":"phase_2"},{"name":"AC-170 0.17%","genericName":"AC-170 0.17%","slug":"ac-170-0-17","indication":"Other","status":"phase_1"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"infectious","drugs":[{"name":"AC-170 0.24%","genericName":"AC-170 0.24%","slug":"ac-170-0-24","indication":"Glaucoma","status":"phase_3"},{"name":"Drug: AC-170 0.24%","genericName":"Drug: AC-170 0.24%","slug":"drug-ac-170-0-24","indication":"Glaucoma","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"AC-150A 0.1%","genericName":"AC-150A 0.1%","slug":"ac-150a-0-1","indication":"Seborrheic dermatitis","status":"phase_2"}]},{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"AC-150B 0.005%","genericName":"AC-150B 0.005%","slug":"ac-150b-0-005","indication":"Treatment of mild to moderate atopic dermatitis","status":"phase_2"}]}],"pipeline":[{"name":"AC-150 Combo","genericName":"AC-150 Combo","slug":"ac-150-combo","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AC-150A 0.1%","genericName":"AC-150A 0.1%","slug":"ac-150a-0-1","phase":"phase_2","mechanism":"AC-150A 0.1% is a topical corticosteroid used to reduce inflammation and itching in various skin conditions.","indications":["Seborrheic dermatitis","Psoriasis"],"catalyst":""},{"name":"AC-150B 0.005%","genericName":"AC-150B 0.005%","slug":"ac-150b-0-005","phase":"phase_2","mechanism":"AC-150B 0.005% is a topical corticosteroid used to reduce inflammation and itching.","indications":["Treatment of mild to moderate atopic dermatitis"],"catalyst":""},{"name":"AC-170 0%","genericName":"AC-170 0%","slug":"ac-170-0","phase":"phase_3","mechanism":"AC-170 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"AC-170 0.05%","genericName":"AC-170 0.05%","slug":"ac-170-0-05","phase":"phase_2","mechanism":"AC-170 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","indications":["Type 2 diabetes"],"catalyst":""},{"name":"AC-170 0.1%","genericName":"AC-170 0.1%","slug":"ac-170-0-1","phase":"phase_2","mechanism":"AC-170 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","indications":["Type 2 diabetes"],"catalyst":""},{"name":"AC-170 0.17%","genericName":"AC-170 0.17%","slug":"ac-170-0-17","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AC-170 0.24%","genericName":"AC-170 0.24%","slug":"ac-170-0-24","phase":"phase_3","mechanism":"AC-170 is a topical ophthalmic agent that reduces intraocular pressure, likely through enhanced aqueous humor outflow or reduced production.","indications":["Glaucoma","Ocular hypertension"],"catalyst":""},{"name":"Drug: AC-170 0.24%","genericName":"Drug: AC-170 0.24%","slug":"drug-ac-170-0-24","phase":"phase_3","mechanism":"AC-170 is a topical ophthalmic agent that reduces intraocular pressure, likely through enhanced aqueous humor outflow or reduced production.","indications":["Glaucoma","Ocular hypertension"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxPdm1LczFlN25RMzEzYkJGUWsyM1poMHFVcHM0VmFuQ0NKdU9rRzk1SXUxR0t1V3piZVBmaXBOSHpHTEtyeE1iN1lHWGpaUy1ISUlYMHNjUWM5eVFHQ2VZTzRVV1hMb1pjSHhrcHZPWXZWZkxzQXlrUFlGclkwdlZaUk96V3liRFk?oc=5","date":"2025-12-11","type":"pipeline","source":"Yahoo Finance","summary":"$73 Billion Non-Opioid Therapeutics Industry Assessment, 2032 Featuring AbbVie, GlaxoSmithKline, Acorda Therapeutics, Allay Therapeutics, Alnylam Pharmaceuticals and Other Key Players - Yahoo Finance","headline":"$73 Billion Non-Opioid Therapeutics Industry Assessment, 2032 Featuring AbbVie, GlaxoSmithKline, Acorda Therapeutics, Al","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAJBVV95cUxPRUVmNFlIZEd3NG50a2p6Z1hWSUI0UnpydUNDWk1VQXNiQ2V4M0s2aGl0LVl6V3lud0JVWWpDTTVTejY2bWktMXVRU2tBR245c2RDSFlTNFZXa1k1YnhzSThQSjZfWXllZmVjQlpJc3c4LWRsVm1wSFZ1UXMtUGt3UEpuN0FQNEt2VVh3SnF5YUhNeTc5eUItcDI4Tzg1dFRacEVZbDB0Z21zU19KeXlzRmU1Umg5TjBPZmh0V1Z1bFYxd3lQT01DVDhlS0FNZklZY3QwSkJpSFlYQXNIRjdCMjRKa3JpTHhLemIwcGhOWlNHNHdfNVlXc0J0OXY5andiLXZBbzRDVFFabkdS?oc=5","date":"2025-12-03","type":"pipeline","source":"VitalLaw.com","summary":"FRAUD AND MANIPULATION—S.D.N.Y.:... - VitalLaw.com","headline":"FRAUD AND MANIPULATION—S.D.N.Y.:...","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxOaHdhNWM3d0JBWmthZTdjdUhmZXpMd1FVT0trbVZ6VXNmMFU3THdjNzR3cDB4RnhVVGVWQVBWWHIxZF9YVldDZ2s5b1I0RmZRWHhiYlp2S082RTZqTDRsM3NZRk1LSFhkZHRoSkpZYjBNZlVDUUthV1VXUlpVT2NDZE9GSk80Y1poeFJqTFh0Y0VhMUJXTlU1OWQzOGJrcTI2N0JaTWNNbnNyWHlEZHJOOVd3WEhRZnVtb0wzNTY2YjNnaFpYTHc?oc=5","date":"2025-08-06","type":"deal","source":"IPWatchdog.com","summary":"License Fraud or Patent Law? Acorda v. Alkermes and the Jurisdictional Trap in Concealed Invalidity Disputes - IPWatchdog.com","headline":"License Fraud or Patent Law? Acorda v. Alkermes and the Jurisdictional Trap in Concealed Invalidity Disputes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxQQVRUWFQyQUpOSG1FYnc5WEtmUWRQcHZJYWdYeHZCTW4zWnQyRHJoODhwR0lfUk9KTzBsLUVJcTRGQVJpYnBldkNqVjRiZnpkZFN0alduWExaVkpjZ2xKM3U5Y1I1RHZ3RVluZG1kSlc2TUhVSjVaOVNORkNsbWZnei1RLUh4WFZqS0dybWRxeTUtR1FaWDFvUnpDVHByMlN1aWdCeTI0UnlwbHdLdDRON2p6dEEzTjd6aXZISW1iOGpwRTNmcmFxWUpNWmZUWTZoQkQyZjFR?oc=5","date":"2024-07-10","type":"pipeline","source":"Business Wire","summary":"Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics - Business Wire","headline":"Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNcEY2Z0p6cnlIbWhFczRnU0FXNU13VEhseVg5U1Z4eVhjXzYtUjFRRTlWcXU2RmhDbEFaRVpjSklVLWxpUFJhRjVyVHdxc0dfS25peUZCeDZRXzd2b1o4MVZ6LW52YWpfRjIteE05cG8xSWRJUEV0WnJyczJTMzFyNkRvbFVZWGlIZ0tFRnNfVDhDOTJDY3VlMlh2NA?oc=5","date":"2024-04-16","type":"pipeline","source":"Pharmaceutical Technology","summary":"Acorda loses Nasdaq listing to cap biotech’s end - Pharmaceutical Technology","headline":"Acorda loses Nasdaq listing to cap biotech’s end","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxPUXlYYldwSF9EMTFXUlpkSEdlMDAyQzZIT2FVZ2FCcm5QS0dTalE4cjdoNDY3a3BnQTVEbHNHTjQ2Qm1YV2wydG5MS1Bic2wtbUp6cWNWeFYyeEo4aDQxTUhjMVFkMFJvQmxJTnFSUUhtdjhaNTltVGlFNmFRUHFCUU1zQWVUNGFnOFpTZDh3MkFNRUdla1dXNTI4WjJPSk9VMmNLcEJoR053R3lYLVk1eUtwNjNFRHpheEhHd2F0NVNxZw?oc=5","date":"2024-04-09","type":"pipeline","source":"Fierce Pharma","summary":"UPDATED: Acorda inks $185M asset sale to Merz, files for bankruptcy after years of disappointing sales - Fierce Pharma","headline":"UPDATED: Acorda inks $185M asset sale to Merz, files for bankruptcy after years of disappointing sales","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxQVktkODdKdWx2X1FxVTFLdnRVVXpOSEY2d0xDU3VZdHpDbTBZOHNleXlGTjR5TTJ3R2t1a3ZzSWxQU2U1a1d4YUZXU0xtYWRRd3RxZHpJV0RCUWlOdm5tQTg1aEZPMF9OcE10UnFTYjBzWGstNUhRelVwRm8yV3k5ZDdwV29sSm1Vck9XUi1STWtaeUFaUzhHa3JJQ2poTWJIdmNLa1FIMndxMXlmNWFxSlozMHFaaS1jdk9hVXVCTUVCZXlsWWNjcFU4UjdjUmJwOU1UblVsQ2tWMU8zVnFWbll1SkJfVF83?oc=5","date":"2024-04-08","type":"pipeline","source":"The Journal News | lohud.com","summary":"Pearl River-based Acorda Therapeutics to close; 97 jobs impacted - The Journal News | lohud.com","headline":"Pearl River-based Acorda Therapeutics to close; 97 jobs impacted - The Journal News | lohud.com","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxPWXdlVVlXUW5McENpWVpzM2NZYVhZQ19RU25OWFZ2NHRZZF9oeTB5RTJrUm1iRHQzNzY0Q253czBTVGNVZEpmTnFuSVF1TXA1S2M1V2dZM2wzUVp2bTlTYzg5d2F4QktQN3dSUUU4NTZTTWxaZzdRU29aYnhGZ0FwTzVYU1E5X3FHUDRrU1JOSEt0dEN2MHc?oc=5","date":"2024-04-02","type":"pipeline","source":"BioPharma Dive","summary":"Acorda files for bankruptcy, reveals asset sale plan - BioPharma Dive","headline":"Acorda files for bankruptcy, reveals asset sale plan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE5vWURTN3lueWtBVHJXMzBCUTAxYXJRWGRRZ0lqcFJZVjlQQlZya1BsU3NHczI0ZmNjOF92WHJTeV8tZnJyOElGYjNET3VFXzZVNnEzT3hYU2VoY2x2MlRPMjZ0YU43TVpSRW93alUyMDBHQjFicmZGaU1vaWR4SjA?oc=5","date":"2024-04-02","type":"deal","source":"businessnc.com","summary":"Merz Therapeutics buying two drugs for $185 million - businessnc.com","headline":"Merz Therapeutics buying two drugs for $185 million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxOSEZiY3ZMS3hDQnVoc1dwYUtTR2VGUmtVcFNPQlNqRjlxWGNJclYtX0tQSW56VWNsRWIwU0U0c2hZN3NuRElRUWIwaXU4MGtYcnp3VGNiT0RHMVg0Q185RHI0RlY0dE5kV24tYjFTdkNnSHhTd3J2Q1JyZlk1aWRuTV9fQzM5bW56WUdSQVQ2NkJuWWFZYmVJY184VVpiQVdKZDJ3dldHdmZlOXVKZ1BQMVp1bjdWaDBMVmQxLTZRc1FTYnBMQUxrMjgwdFRCVFBJVktmdURVeHVHVXp5ZFFjQm11My1weExLUnlISjh3?oc=5","date":"2023-05-08","type":"pipeline","source":"PR Newswire","summary":"Chance Pharmaceuticals and Acorda Therapeutics Announce Agreement to Provide INBRIJA® in Greater China - PR Newswire","headline":"Chance Pharmaceuticals and Acorda Therapeutics Announce Agreement to Provide INBRIJA® in Greater China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNYm1GTlJIM3gxWFo1OW4xNU56bHZsOGl5a1NUNkpBOTZXaXY5Nm1TSGxSd0wzVENoQ1p6Q25wZTkxN3JyZ2lYT1hiRGgydC02Mk1qZ2tMNWNJTzV3VFZ4Y0dsQWxPeWtGYTVBdFpKLVI3Z2ZMbzJXYy14ZVA0eFJ5SHNpNm53YVlESFY1Q0VJbTRPU2R2cl9TampVSm9GT1MwY25GSm1lRzRmZw?oc=5","date":"2021-02-19","type":"pipeline","source":"Drug Delivery Business","summary":"Acorda Therapeutics announces departure of business operations chief - Drug Delivery Business","headline":"Acorda Therapeutics announces departure of business operations chief","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNQnZJdW4wRVl0a0xIb0hPNGs4NHluVnZfNWdET3hHdE5waXpvNzJJQTY0VFpUbFJrNzFPX1VmQ0xQMUhHNEthRWVsQWV4eUF1YmdJQWpzaGZHd2ZodWFFT3JWU3R5SjhUMjRqa2NGS3I1cGs4M3B6TkY5QVBSdDhtVk1iYmd2MG0teHJ6bjdNT2RsaWVubVVoSWVvNlE3bFhiVDVqZ0puMEg3MjFsSzhFbTBpaVlOd1lpUnVJaQ?oc=5","date":"2020-11-12","type":"pipeline","source":"Mintz","summary":"In Hatch-Waxman litigation, Federal Circuit restricts venue under the TC Heartland to districts relating to ANDA filings - Mintz","headline":"In Hatch-Waxman litigation, Federal Circuit restricts venue under the TC Heartland to districts relating to ANDA filings","sentiment":"neutral"}],"patents":[],"drugCount":9,"phaseCounts":{"phase_2":5,"phase_3":3,"phase_1":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}